Targeted immunotherapy alone probably leads to lower 1‐year mortality compared with standard targeted therapies (moderate certainty).
Targeted immunotherapy alone probably leads to higher quality of life: Clinically relevant improvement in FKSI‐DRS compared with standard targeted therapies (moderate certainty).
Targeted immunotherapy alone probably leads to lower adverse events (grade ≥ 3) compared with standard targeted therapies (moderate certainty).
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).